Cargando…

Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges

Non-alcoholic fatty liver disease (NAFLD) is emerging as a major health problem worldwide. NAFLD is a continuum of disease ranging from mild liver steatosis to severe steatohepatitis, which will ultimately lead to end-stage liver disease with high morbidity and mortality rates. This disorder is cons...

Descripción completa

Detalles Bibliográficos
Autores principales: Dooghaie Moghadam, Arash, Eslami, Pegah, Razavi-Khorasani, Niloofar, Moazzami, Bobak, Zahedi-Tajrishi, Farbod, Farokhi, Ermia, Makhdoomi Sharabiani, Kamyab, Mansour-Ghanaei, Alireza, Mehrvar, Azim, Aghajanpoor Pasha, Morteza, Saeedi, Sandra, Iravani, Shahrokh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Babol University of Medical Sciences 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911758/
https://www.ncbi.nlm.nih.gov/pubmed/33680375
http://dx.doi.org/10.22088/cjim.11.4.346
_version_ 1783656417187594240
author Dooghaie Moghadam, Arash
Eslami, Pegah
Razavi-Khorasani, Niloofar
Moazzami, Bobak
Zahedi-Tajrishi, Farbod
Farokhi, Ermia
Makhdoomi Sharabiani, Kamyab
Mansour-Ghanaei, Alireza
Mehrvar, Azim
Aghajanpoor Pasha, Morteza
Saeedi, Sandra
Iravani, Shahrokh
author_facet Dooghaie Moghadam, Arash
Eslami, Pegah
Razavi-Khorasani, Niloofar
Moazzami, Bobak
Zahedi-Tajrishi, Farbod
Farokhi, Ermia
Makhdoomi Sharabiani, Kamyab
Mansour-Ghanaei, Alireza
Mehrvar, Azim
Aghajanpoor Pasha, Morteza
Saeedi, Sandra
Iravani, Shahrokh
author_sort Dooghaie Moghadam, Arash
collection PubMed
description Non-alcoholic fatty liver disease (NAFLD) is emerging as a major health problem worldwide. NAFLD is a continuum of disease ranging from mild liver steatosis to severe steatohepatitis, which will ultimately lead to end-stage liver disease with high morbidity and mortality rates. This disorder is considered as a silent liver disease. The metabolic syndrome and its components are accounted as the major risk factors for the progression of NAFLD to NASH and cirrhosis. Liver transplantation is considered as an appropriate treatment for the end-stage disease. For the last two decades, NASH has been the most common reason for liver transplantation, especially in the developed countries; however, the outcome of post-transplantation in these patients is of a great concern. The recurrent NASH and NAFLD seem to be the usual issues in LT. Steatosis appears in more than 80% of LTs; however, re-transplantation caused by steatohepatitis is rare. Recently, several risk factors of the recurrent NAFLD, including age, donor steatosis, metabolic syndrome, and immunosuppressant agents, have been introduced. Among the metabolic syndrome components, obesity seriously has negative effects on the outcomes of post-liver transplantation in patients. Unfortunately, there is no standard medicine to prevent or treat the recurrent NAFLD; however, it seems that weight loss and lifestyle modification play critical roles in controlling or inhibiting the recurrent NAFLD or NASH.
format Online
Article
Text
id pubmed-7911758
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Babol University of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-79117582021-03-04 Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges Dooghaie Moghadam, Arash Eslami, Pegah Razavi-Khorasani, Niloofar Moazzami, Bobak Zahedi-Tajrishi, Farbod Farokhi, Ermia Makhdoomi Sharabiani, Kamyab Mansour-Ghanaei, Alireza Mehrvar, Azim Aghajanpoor Pasha, Morteza Saeedi, Sandra Iravani, Shahrokh Caspian J Intern Med Review Article Non-alcoholic fatty liver disease (NAFLD) is emerging as a major health problem worldwide. NAFLD is a continuum of disease ranging from mild liver steatosis to severe steatohepatitis, which will ultimately lead to end-stage liver disease with high morbidity and mortality rates. This disorder is considered as a silent liver disease. The metabolic syndrome and its components are accounted as the major risk factors for the progression of NAFLD to NASH and cirrhosis. Liver transplantation is considered as an appropriate treatment for the end-stage disease. For the last two decades, NASH has been the most common reason for liver transplantation, especially in the developed countries; however, the outcome of post-transplantation in these patients is of a great concern. The recurrent NASH and NAFLD seem to be the usual issues in LT. Steatosis appears in more than 80% of LTs; however, re-transplantation caused by steatohepatitis is rare. Recently, several risk factors of the recurrent NAFLD, including age, donor steatosis, metabolic syndrome, and immunosuppressant agents, have been introduced. Among the metabolic syndrome components, obesity seriously has negative effects on the outcomes of post-liver transplantation in patients. Unfortunately, there is no standard medicine to prevent or treat the recurrent NAFLD; however, it seems that weight loss and lifestyle modification play critical roles in controlling or inhibiting the recurrent NAFLD or NASH. Babol University of Medical Sciences 2020 /pmc/articles/PMC7911758/ /pubmed/33680375 http://dx.doi.org/10.22088/cjim.11.4.346 Text en Copyright © 2020, Babol University of Medical Sciences This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Dooghaie Moghadam, Arash
Eslami, Pegah
Razavi-Khorasani, Niloofar
Moazzami, Bobak
Zahedi-Tajrishi, Farbod
Farokhi, Ermia
Makhdoomi Sharabiani, Kamyab
Mansour-Ghanaei, Alireza
Mehrvar, Azim
Aghajanpoor Pasha, Morteza
Saeedi, Sandra
Iravani, Shahrokh
Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges
title Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges
title_full Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges
title_fullStr Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges
title_full_unstemmed Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges
title_short Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges
title_sort recurrence of fatty liver disease following liver transplantation for nafld-related cirrhosis: current status and challenges
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911758/
https://www.ncbi.nlm.nih.gov/pubmed/33680375
http://dx.doi.org/10.22088/cjim.11.4.346
work_keys_str_mv AT dooghaiemoghadamarash recurrenceoffattyliverdiseasefollowinglivertransplantationfornafldrelatedcirrhosiscurrentstatusandchallenges
AT eslamipegah recurrenceoffattyliverdiseasefollowinglivertransplantationfornafldrelatedcirrhosiscurrentstatusandchallenges
AT razavikhorasaniniloofar recurrenceoffattyliverdiseasefollowinglivertransplantationfornafldrelatedcirrhosiscurrentstatusandchallenges
AT moazzamibobak recurrenceoffattyliverdiseasefollowinglivertransplantationfornafldrelatedcirrhosiscurrentstatusandchallenges
AT zaheditajrishifarbod recurrenceoffattyliverdiseasefollowinglivertransplantationfornafldrelatedcirrhosiscurrentstatusandchallenges
AT farokhiermia recurrenceoffattyliverdiseasefollowinglivertransplantationfornafldrelatedcirrhosiscurrentstatusandchallenges
AT makhdoomisharabianikamyab recurrenceoffattyliverdiseasefollowinglivertransplantationfornafldrelatedcirrhosiscurrentstatusandchallenges
AT mansourghanaeialireza recurrenceoffattyliverdiseasefollowinglivertransplantationfornafldrelatedcirrhosiscurrentstatusandchallenges
AT mehrvarazim recurrenceoffattyliverdiseasefollowinglivertransplantationfornafldrelatedcirrhosiscurrentstatusandchallenges
AT aghajanpoorpashamorteza recurrenceoffattyliverdiseasefollowinglivertransplantationfornafldrelatedcirrhosiscurrentstatusandchallenges
AT saeedisandra recurrenceoffattyliverdiseasefollowinglivertransplantationfornafldrelatedcirrhosiscurrentstatusandchallenges
AT iravanishahrokh recurrenceoffattyliverdiseasefollowinglivertransplantationfornafldrelatedcirrhosiscurrentstatusandchallenges